August 15, 2024
Avicanna Reports Q2 2024
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on…
Pharmaceuticals, Biotechnology and Life Sciences
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on…
Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation…
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court’s approval of…
WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company,…
MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage…
Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of…
Company to host conference call on August 15, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE)…
Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action…
Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for…
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development…